Contingencies for Biopharma, Medtech Deal Planning in a Down Market

Back Bay Life Science Report

For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clinical setting.

In a down market, there are creative and thoughtful approaches companies can take to stand out as capital becomes more closely guarded and the competition becomes fierce.

In this episode of Back Bay’s industry podcast, the Life Science Report, Jonathan Gertler speaks with Goodwin Procter life science partner Kristopher Brown about the current market landscape and how life science companies can recalibrate and prepare for capital raises—no matter the market outlook.

This episode focuses on discussion of deal management in the current market, including:

• The current deal scape—difficult times ahead or par for the course in the life science sector?
• Approaches to deal preparation in a challenging environment
• Tentative M&A, licensing, partnering activity and public markets necessitate preparation and strategic focus ahead of capital raise, particularly:
  • Thorough knowledge of asset differentiation - positioning, competitive intensity, pricing, milestone development/definition and valuation, among other activities
• Creative deal financing models – royalty monetization, tranced investments, debt financing, preferred stock, liquidation preferences
• Structure and valuation discipline
• Portfolio and selection management toward a deal, including the use of AI in population identification

Find the video podcast and contribute to the conversation on Back Bay’s website: www.bblsa.com/podcasts